Role: Lead the development and execution of a Celgene I&I program/compound development/Life Cycle strategy. Responsible for creating the overall program/compound’s development/life Cycle strategy.
Lead program/project team(s) to develop integrated cross-functional program/compound implementation plan based on the governance committee approved development/life cycle strategy. etc on corp website
Often, the analysts' expectations are already priced in the stock. That's why I took profits in my CELG short last Thursday. I haven't gone long at this price and won't until after the quarterly report (if warranted).
Maybe CELG can design a drug that prevents people from saying stupid things while public speaking. I'm sure Yellen could use it.
My mother in law could use that too...
Janet Yellen needs to stay in her lane. She is way out of line making comments like she is a biotech analyst.
Reason to own is they will be bought out. To many starved big Pharm a's for growth and a pipeline.
Estimates are at $.89! I suspect a slight beat...but, who knows?
The beauty of owning CELG is their pipeline...
Just own the stock, and do not worry about the quarterly reports
And the forward PE 12 month out would stay the same. If they come anywhere near...look out.
1-No available cash on hand
2-No experience in Bio Med
3-The CEO has no experience running a Bio Med
4-The Chief Science Officer has not been heard from in months
5-The CFO is retired
6-No reporting on insider trading
7-Always late reporting 10-k/10-q
8-Recent shady deal with LPC
9-Alleged involvement in too many hot topic areas
10-History of paid stock promotion
11-No institutional investment ever
12-No ability to raise money
13-Changing business model every few years
14-Once claimed they had a natural cancer cure
15-Not one penny spent on research
16-Promise of Phase 3 clinical trial is now a Pre Clinical study
17-History of not paying bills instead they settle debt with stock payments
18-Recent bogus PRs grounds for SEC fraud indictment
Sentiment: Strong Sell
Almost no volume in in the money CELG calls expiring today - they want the shares called into acct - over 25,000 calls (36,000 if over 85) about 2.5 million (3.6 mill) shares will be taken from people who wrote them....
might be positive for today's action and and especially next week.
An Open Letter To Janet Yellen: Is There A Biotech Bubble?
7/18/2014 @ 8:24AM
Mark Schoenebaum, the lead health care analyst at International Strategy & Investment Group, sent the following open letter to his clients this morning, in response to comments by Fed chair Janet Yellen that have left both the iShares Nasdaq Biotechnology Index and bellwethers like Celgene, Gilead, and Biogen Idec all down 5% for the week.
I think it’s worth reprinting — I’ve added the headers and changed some punctuation.
The Honorable Janet Yellen, Ph.D.
Board of Governors of the Federal Reserve System
Constitution Ave NW, Washington, DC 20551
Dear Dr. Yellen:
Thank you for sharing your thoughts recently on the biotech sector. Given your stature, I paid very close attention to your comments, as did most biotech observers.
You stated that biotechnology valuations are “stretched, with ratios of prices to forward earnings remaining high relative to historical norms.”
I just gathered biotech price to earnings ratios back to 1993 using Russell 1000 data, and my data show that the current ratio is roughly in-line with the historical median and is approximately 80% below the peak.
Please tell me what I’m missing, Dr. Yellen.
Senior Managing Director
Head of Healthcare Research
International Strategy And Investing Group
18. NEGATIVE !!!! retained earnings $52,000,000
Founded 1996. Purpose of existence: to supply jobs to managers who would otherwise be bartenders.
Horrible! Only a fool would buy this turkey.